title: Stimulation of both dopamine D1 and D2 receptors facilitates in vivo acetylcholine release in the hippocampus.
abstract: The effect of selective D1 and D2 dopamine (DA) receptor agonists and of a mixed D1/D2 agonist on hippocampal acetylcholine (ACh) release was investigated. LY 171555 (0.5 and 1 mg/kg, i.p.), SKF 38393 (1 to 10 mg/kg, i.p.), CY 208-243 (0.2 mg/kg, i.p.) and apomorphine (0.5 to 2 mg/kg, i.p.), at doses stimulating rat behavior, were found to increase the output of ACh in the hippocampus. Maximal increase was observed after LY 171555 1 mg/kg, SKF 38393 10 mg/kg, CY 208-243 2 mg/kg and apomorphine 2 mg/kg (85, 90, 87 and 210%, respectively). The enhancement of ACh release induced by either SKF 38393 (10 mg/kg) or LY 171555 (1 mg/kg) was prevented by the blockade of D1 receptors with SCH 23390 (0.1 mg/kg, s.c.). Co-administration of maximally active doses of LY 171555 (1 mg/kg) and SKF 38393 (10 mg/kg) produced an additive effect (about 200%). In contrast to the findings with high doses, low, presynaptic doses of LY 171555 and apomorphine reduced ACh output. Maximal reduction was observed after 0.05 mg/kg for both drugs, (43 and 52%, respectively). These results show that activation of dopaminergic transmission either at D1 and/or at D2 receptors enhances ACh output in the hippocampus.
authors.affiliation: Bernard B. Brodie Department of Neuroscience, University of Cagliari, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Imperato
authors.forename: M C
authors.initials: MC
authors.lastname: Obinu
authors.forename: G L
authors.initials: GL
authors.lastname: Gessa
mesh_terms: D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D003956:Dialysis; D015259:Dopamine Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000037:antagonists & inhibitors / Q000494:pharmacology; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism*; D007211:Indoles / Q000494:pharmacology; D008297:Male; D010617:Phenanthridines / Q000494:pharmacology; D019257:Quinpirole; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000187:drug effects*; D017448:Receptors, Dopamine D2 / Q000187:drug effects*
chemical_list: D015259:Dopamine Agents; D004873:Ergolines; D007211:Indoles; D010617:Phenanthridines; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; C054531:CY 208-243; D019257:Quinpirole; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D001058:Apomorphine; D000109:Acetylcholine